From:  Lorlatinib in advanced ALK-positive NSCLC after prior progression on ALK inhibitors: real-world experience in Russia

 Evaluation of the tumor’s response to lorlatinib.

Efficacy endpointsOverallNumber of prior ALK TKIResponse to prior ALK TKI
1 line≥ 2 linesp≤ 12 months> 12 monthsp
ORR, n (%)53/82 (64.6)39/62 (62.9)14/20 (70.0)0.60418/31 (58.1)35/51 (68.6)0.351
DCR, n (%)79/82 (96.3)60/62 (96.8)19/20 (95.0)1.00028/31 (90.3)51/51 (100.0)0.051
IC-ORR, n (%)43/65 (66.2)34/49 (69.4)9/16 (56.3)0.37214/25 (56.0)29/40 (72.5)0.190
IC-DCR, n (%)63/65 (96.9)47/49 (95.9)16/16 (100.0)1.00023/25 (92.0)40/40 (100.0)0.144

ALK: anaplastic lymphoma kinase; ORR: objective response rate; DCR: disease control rate; IC-ORR: intracranial objective response rate; IC-DCR: intracranial disease control rate; TKI: tyrosine kinase inhibitor.